39 results about "Pregnanetriolone" patented technology

A pharmaceutical formulation comprising a self-emulsifying drug delivery system comprising dydrogesterone or a pharmaceutically acceptable salt thereof, as well as methods of making and using the same.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

Provided are methods of contraception using as a first line combined oral contraceptive (COC), a COC composition comprising nomegestrol acetate (NOMAC) and estradiol or an ester thereof. Said COC compositions are associated with a lower risk of venous thromboembolism (VTE) as compared to other CHCs. The compositions may also be used in methods of treatment in women having conditions linked to menstruation and / or fertility.

A pharmaceutical formulation comprising a self-emulsifying drug delivery system comprising dydrogesterone or a pharmaceutically acceptable salt thereof, as well as methods of making and using the same.

The application provides use of zanamivir in preparation of a medicine for treating or preventing preeclampsia, and a corresponding medicine and treatment method; zanamivir can effectively improve high blood pressure, proteinuria, creatinine, neuraminidase and sialic acid elevation symptoms of preeclampsia, increase NO level, and improve pregnancy outcome. Zanamivir and hydroxyprogesterone caproate in combination show better effects.

The invention discloses a method for improving heterologous synthesis of pregnenolone and progesterone by using yarrowia lipolytica. The invention provides a method for improving the heterologous synthesis of pregnenolone by using yarrowia lipolytica, which comprises the following steps: knocking out an MHY1 gene on the basis of a recombinant yarrowia lipolytica strain SyBEY12090002, and constructing a strain Y1001; the invention relates to a method for improving heterologous synthesis of progesterone by using yarrowia lipolytica, which is characterized in that on the basis of a recombinant yarrowia lipolytica strain SyBEY12090002, 3beta-hydroxysteroid dehydrogenase is introduced, an MHY1 gene is knocked out, and a strain Y1102 is constructed. The MHY1 gene is knocked out from the strain for synthesizing the pregnenolone or the progesterone from the beginning, so that the yield of the pregnenolone or the progesterone synthesized by the recombinant lipolytic yeast strain is improved, the influence of regulating the morphological change of the yarrowia lipolytica on a heterologous synthesis pathway is explored, and a research direction is provided for subsequently improving the yield of the pregnenolone or the progesterone.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI). vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.

This disclosure relates to progesterone phosphate derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation such as those resulting from traumatic brain injury or stroke.

The invention relates to the technical field of biology, in particular to a dissociation agent and a kit for progesterone determination. According to the invention, the sample dissociation agent for progesterone detection is obtained through optimized screening, and the sample dissociation agent comprises hydrocortisone, prednisolone and mono (2-ethylhexyl) phthalate (MEHP); when the dissociation agent components act independently or in a combined mode, the sensitivity to sample detection is high, the detection linear range is good, the dissociation agent is well related to a comparison reagent, the dissociation effect is improved remarkably on the whole, progesterone can be better released from corticosteroid binding protein, albumin and sex hormone binding globulin, and the progesterone dissociation agent is suitable for being used for detecting progesterone. The combination of progesterone and a captured antibody is facilitated, and the sensitivity and the accuracy can be effectively improved. Moreover, the reagent can be directly added into reagent components, so that the dissociation process and the immune reaction are carried out at the same time, the immune reaction is simple and efficient, and the reaction efficiency is improved.

The application relates to the technical field of traditional Chinese medicine, and discloses a preparation method of a medicine for lactation promotion of puerpera. The medicine composition for treating dysfunctional uterine bleeding is originally used for treating excessive menstruation and prolonged menstruation of women. The improved preparation method uses a supercritical CO2 extraction method to extract volatile oil, so that the medicine composition for treating dysfunctional uterine bleeding has higher efficacy and can be fully exerted. Through experiments, it is verified that when the improved medicine composition is used for lactation promotion of puerpera, the medicine composition can help to increase the levels of estradiol and progesterone hormones to regulate hormone imbalance, act on developed mammary glands to promote the increase of lactation, and has small toxic and side effects and reduces the burden of the liver.

Use of a composition comprising nomegestrol acetate and estradiol or one of its esters for reducing the risk of venous thromboembolism associated with the use of combined oral contraceptives; wherein the risk of venous thromboembolism associated with the use of the composition is not higher than the risk of venous thromboembolism associated with the use of a combined oral contraceptive containing levonorgestrel.

The invention relates to a preparation method of medroxyprogesterone acetate. The preparation method of medroxyprogesterone acetate comprises the following steps: mixing 17alpha-hydroxyprogesterone with glacial acetic acid, acetic anhydride and a first catalyst for first reaction to prepare an intermediate 1; mixing the intermediate 1 with tetrahydrofuran, ethanol, triethyl orthoformate and a second catalyst to carry out a second reaction, then adding formaldehyde and N-methylaniline to carry out a third reaction, then adding hydrochloric acid and water to carry out a fourth reaction, and collecting a crude product of an intermediate 2; and preparing the medroxyprogesterone acetate through a series of refining steps. According to the preparation method, the dosage of the palladium-carbon catalyst is small, the cost can be obviously reduced, and the product is lower in impurity content and higher in purity.

The purpose is to provide plasma biomarkers for bone infections in humans. [Solution] The plasma biomarker for bone infection consists of one or more substances selected from the group consisting of sphingosine-1-phosphate, taurocholic acid, glycololic acid, 11a,b-hydroxyprogesterone, 15(S)-HETE-2, 13-dehydrochenodeoxycholic acid, 3,21-dihydroxy-5a-pregnan-20-one-2, aldosterone, bisacrone-2, naringenin, tauro-a-muricholic acid-6, 1-deoxysphingosine, 12(S)-HETE-2, 2-arachidonoylglycerol, 3-hydroxydodecanoic acid, 3-hydroxytetradecanoic acid, 3b-hydroxy-5-cholestenoic acid, AEA(22:4)-1, AEA(22:4)-2, bilverdin, sphingosine, malic acid, and succinic acid.

The invention discloses a method for timed insemination of gilts for optimizing hormone usage patterns, comprising: 1) selecting gilts: selecting gilts in estrus, wherein the estrus span of the selected gilt group is within 11 days; 2) performing synchronization treatment: feeding alkaloids to gilts that are in estrus on the 1st, 2nd, 3rd, 4th, 5th and 6th days respectively starting from the 16th day after estrus, and continuously feeding them for 12, 11th, 10th, 9th, 8th and 7th days respectively; and feeding alkaloids to gilts that are in estrus on the 7th, 8th, 9th, 10th and 11th days respectively starting from the 15th, 14th, 13th, 12th and 11th days after estrus, and continuously feeding them for 7 days; 3) performing superovulation; and 4) artificial insemination. The present invention reduces the treatment time of progesterone hormones, reduces the usage amount of progesterone hormones, reduces the application cost and the return to estrus ratio, and improves the reproductive traits of gilts such as the first-time breeding conception rate, the first-time weaning estrus rate, and the average number of piglets born in the second litter.

This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation resulting from traumatic brain injury or stroke.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of a Dan'e Fukang preparation in preparation of a medicine for treating premature ovarian failure. The invention provides application of a Dan'e Fukang preparation in preparation of a medicine for treating premature ovarian failure. Experiments prove that the Dan'e Fukang preparation can improve uterus and ovarian organ indexes of premature ovarian failure mice; the contents of estradiol and progesterone in the serum of the premature ovarian failure mouse are improved. The Dan'e Fukang preparation can reduce the FSH level and the LH level in the serum of a premature ovarian failure rat, and can significantly increase the E2 level of the rat; the Dan'e Fukang preparation disclosed by the invention can be used for inhibiting premature ovarian failure and promoting ovarian function recovery.

The present disclosure relates to the use of neuroactive steroids, including alfaxalone, alfadolone, alfadolone acetate, pregnanediol, pregnanolone, ent-pregnanolone, pregnanedione, allopregnanediol, allopregnanedione, acebrochol, ganaxolone, hydroxydione, minaxolone, renanolone, (2β,3α,5β)-21-chloro-3-hydroxy-2-morpholin-4-ylpregnan-20-one (Org-20599), 2β-(2,2-dimethyl-4-morpholinyl)-3α-hydroxy-11,20-dioxo-5α-pregnan-21-yl methanesulfonate (Org-21465), 20-(hydroxyimino)pregn-4-en-3-one (EIDD-036), posovolone (Co 134444), zuranolone (SAGE-217), 3α-hydroxy-3β- methyl-21-(pyrazolo[3',4'-c]pyridin-2'-yl)-19-nor-5β-pregnan-20-one (SGE-872), alfaxalone / alfadolone (CT1341), (3β,5β,17β)-3-hydroxyandrostane-17-carbonitrile (3β- OH), (3α,5α)-3-hydroxy-13,24-cyclo-18,21-dinorchol-22-en-24-ol (CDNC24), 3α- dihydroprogesterone (3α-DHP), ent-progesterone, dihydrodeoxycorticosterone (DHDOC), tetrahydrodeoxycorticosterone (THDOC), and betaxalone, for treating or at least partially inhibiting the development or progression of an infection caused by a neurotropic virus in a subject. This disclosure also relates to the use of neuroactive steroids for treating or at least partially inhibiting the development or progression of a condition associated with an infection caused by a neurotropic virus, such as encephalopathy or acute encephalitis.

The invention relates to the field of preparation of steroid drugs, and discloses a preparation method of didrogesterone. The preparation method disclosed by the invention comprises the following steps: by taking 9beta, 10alpha-pregna-4, 7-diene-3, 20-diketone as a starting material, carrying out intramolecular 7, 8-double bond transposition in the presence of organic silicon Lewis acid, so as to obtain the didrogesterone. The preparation method of the didrogesterone, provided by the embodiment of the invention, has the beneficial effects that (1) the purity of a refined product can reach 99% or above, the impurity content is controllable, and the total yield can be increased to 85% or above; reaction conditions are mild, operation is simple, and the method is suitable for industrial production.

The aim is to provide plasma biomarkers for bone infections in humans. [Solution] A plasma biomarker for bone infection comprising one or more substances selected from the group consisting of sphingosine-1-phosphate, taurocholic acid, glycololic acid, 11a,b hydroxyprogesterone, 15(S)-HETE-2, 13-dehydrochenodeoxycholic acid, 3,21-didihydroxy-5a-pregnane-20-one-2, aldosterone, bisacron-2, naringenin, tauro-α-mulicolic acid-6, 1-deoxysphingosine, 12(S)-HETE-2, 2-arachidonoylglycerol, 3-hydroxydodecanoic acid, 3-hydroxytetradecanoic acid, 3b-hydroxy-5-cholestic acid, AEA(22:4)-1, AEA(22:4)-2, bilbertin, sphingosine, malic acid, and succinic acid.

The invention relates to the technical field of cell engineering and biopharmacy, and discloses a method for promoting synthesis of steroids in forest musk gland cells, which comprises the following steps: determining the tolerance range of cholesterol concentration through a pre-experiment, setting an experimental group, culturing cells, collecting and treating a sample, and detecting by LC-MS (Liquid Chromatography-Mass Spectrometry). According to the method for promoting synthesis of the steroids in the lindel gland cells, the synthesis amount of the seven steroids in the lindel gland cells can be up-regulated by regulating the cholesterol concentration of the culture medium to 10-20 mg / L, the content of pregnenolone is up-regulated by 4.12 times (Plt, 0.05), the content of progesterone is up-regulated by 1.46 times (Plt, 0.05), and the method is remarkably superior to that of existing culture without cholesterol regulation; a complete standardized process from pre-experiment, culture, sample treatment to detection is provided, the experiment result repeatability is high, and the method can be directly applied to industrial production.

The application discloses a preparation method of levonorgestrel, which comprises the following steps: iodine substitution is carried out on 18-hydroxy-4-estrene-3,17-dione to obtain a compound shown in formula 1; acetylene addition is carried out on the compound shown in formula 1 to obtain a compound shown in formula 2; ketal protection is carried out on the compound shown in formula 2 to obtain a compound shown in formula 3; methylation is carried out on the compound shown in formula 3 to obtain a compound shown in formula 4; and hydrolysis ketal reaction is carried out on the compound shown in formula 4 to obtain levonorgestrel. The preparation method is simple in operation, high in safety and friendly to environment, greatly reduces the safety, environmental protection and compliance costs in process production, is low in price of auxiliary materials, easy to purchase and convenient for industrial production and purchase, and is high in conversion rate.

The invention relates to a biomarker for diagnosing 17 alpha-hydroxylase deficiency and application of the biomarker. The biomarkers comprise 5 [alpha]-dihydroprogesterone, 17 hydroxyl-dihydroprogesterone, 17 hydroxyl-tetrahydroprogesterone, androsterone, androstanediol and dihydrotestosterone. According to the method disclosed by the invention, a biomarker for diagnosing the 17 alpha-hydroxylase deficiency is deeply mined and analyzed based on a liquid chromatography-mass spectrometry technology, an efficient screening tool is further developed, and high-specificity, high-sensitivity and high-accuracy auxiliary screening of the 17 alpha-hydroxylase deficiency is realized.

The utility model relates to the field of gynecological appliances, in particular to a comprehensive Genimann-Luolele structure capable of releasing medicine by using a copper ring. The upper part of the fixing line can be nailed and hung in the uterine cavity; a plurality of copper rings are arranged on the fixing line in a penetrating manner, an upper bracket is arranged above a copper ring body, and a lower bracket is arranged below the copper ring body; the fixing line penetrates through the penetrating holes in the upper support and the lower support. The lower support can support medicine arranged in the copper ring, and the medicine is levonorgestrel. After the Munule and the Gini ring are combined into one and refitted, the Munule is fixed in the uterine superficial muscle layer through the Gini knot, the problems that the Munule moves downwards and falls off are perfectly solved, the treatment effect is achieved, and meanwhile the efficient and long-acting contraception effect is achieved for women with contraception requirements.

The invention relates to an androgen back door pathway hormone detection kit, a detection method and application. The detection method comprises the following steps: pretreating a to-be-detected sample, and then carrying out liquid chromatography-tandem mass spectrometry detection; the pretreatment comprises the following steps: mixing the to-be-detected sample with an internal standard, adding an extracting agent, centrifuging, taking supernate, drying, and redissolving by using a redissolving agent; the extracting agent comprises a mixed solution of ethyl acetate and n-hexane; the resolvent comprises a methanol aqueous solution. The kit and the LC-MS / MS detection method for simultaneously detecting 5 alpha-dihydroprogesterone, 17 hydroxyl-dihydroprogesterone, 17 hydroxyl-tetrahydroprogesterone, androsterone, androstanediol and dihydrotestosterone are designed, rapid and accurate detection is achieved, high sensitivity is achieved, the kit and the method can be effectively applied to auxiliary diagnosis of 17 alpha-hydroxylase deficiency diseases, especially atypical 17 alpha-hydroxylase deficiency diseases and other diseases, and the clinical application prospect is wide. The method has high practical application value.

The invention belongs to the technical field of medicine preparation, discloses a Jinfeng pill for treating ovary and functional damage thereof and a preparation method, and solves the problems of low extraction rate of cornu cervi pantotrichum polypeptide and easy blistering in concentration in the traditional process. During preparation, fresh cornu cervi pantotrichum is subjected to slicing, freeze-drying and low-temperature crushing and then is subjected to closed self-enzymolysis for several hours with several times of water at a certain temperature, the content of cornu cervi pantotrichum polypeptide in the extract reaches 8%-15% by combining ultrafiltration membrane treatment and segmented concentration, and dissipation of effective components during concentration is avoided. A levonorgestrel-induced rat ovarian injury model verifies that the medicine can restore the estrus cycle, reverse ovarian uterine atrophy, improve the ovarian pathological morphology, regulate the serum hormone level and effectively repair the ovarian function, and an efficient Chinese patent medicine and a preparation scheme are provided for clinic.

Disclosed are: a poultry feed comprising at least one selected from the group consisting of progesterone, pregnenolone, and medroxyprogesterone; and a method for breeding poultry, the method comprising a step for causing poultry to ingest at least one selected from the group consisting of progesterone, pregnenolone, and medroxyprogesterone.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a biological oxidation preparation method of a key intermediate in a chemical synthesis medicine production process. A compound A synthesized by photocatalytic isomerization of pregnenolone is used as a raw material. Under the action of alcohol dehydrogenase, the compound A is oxidized to form a compound B, and then the compound B is shifted in a hydrogen chloride ethanol solvent to form the didrogesterone. Through the preparation technology provided by the invention, the high-purity didrogesterone bulk drug can be obtained with low cost and high efficiency.